Editor's note: This article is fromInvestment communityLiu Fujuan, the author, was authorized to reprint 36 krypton at sea.
In the era of three births, assisted reproduction became popular.
The latest financing is the assisted reproductive brand Weituo Biology, which has just completed a hundred million yuan round C financing, led by the CICC Qichen Fund under CICC Capital, followed by Zhang Keherun and Xiangrong Capital. Surprisingly, this is the second round of financing of Veto Bio this year.
It was found that since this year, at least five assisted reproduction companies have completed financing - Weituo Biology, Nuwa Life, Hewanjia Hospital, DHC Medical, and Haoyunbang. Behind them, there are a number of investment institutions such as CICC Qichen Fund, Songhe Capital, and Dingxin Capital. Here comes the scene: the VC of medical investment began to appear this track frequently.
There is a worthy overlord in the "human creation" Jianghu——Jinxin reproduction。 Located in Chengdu, Sichuan, Jinxin Reproduction is the only private assisted reproductive hospital in the head, serving more than 20000 cases a year. In 2019, Jinxin Reproduction went to the Hong Kong Stock Exchange for listing. At that time, the prospectus cited Frost Sullivan's report, which showed that there were about 47.7 million infertile couples in China. At present, the market value of Jinxin Reproduction has reached HK $32 billion.
After the opening of the three child policy, assisted reproductive technology has brought a ray of good news to those families who "want to have children but cannot".
A rare amount of financing
Now, medicalVC is looking at assisted reproduction
Assisted reproduction caught fire unexpectedly.
According to incomplete statistics, at least five companies have successively obtained financing this year, namely Weituo Biology, Nuwa Life, Hewanjia Hospital, DHC Medical, and Haoyunbang. The investors behind them include VC/PE institutions such as CICC Qichen Fund, Songhe Capital, Dingxin Capital, and the listed company Jinxin Reproduction.
Among them, Weituo Bio has completed two rounds of financing this year. This is an enterprise established in 2015, focusing on products and technologies related to assisted reproduction laboratories. In 2021, Weituo Bio has three products: vitrified cryogen, vitrified thaw and gamete buffer, which have won the Class III registration certificate of China NMPA, and are the first domestic reagents of the same type approved, breaking the long-term monopoly of foreign brands on key technologies in assisted reproduction laboratories.
Behind Weituo Biology is Lin Xiaozhen, a female founder, and G á bor Vajta, an embryologist. Since its establishment, Weituo Bio has won the favor of many VCs/PEs, and has completed six rounds of financing, including CICC Capital, Zhangjiang Ketou, Rural Revitalization Fund RFUND, Wang Weiwei No. 10 Investment, Daotong Investment, Weilai Capital, Zhuoshi Capital, Danlu Capital, Investment Holding Donghai, Power Capital, Yanghe Industry and Germany.
"In 2021, the country will fully open the three child policy, and in the Decision of the Central Committee of the Communist Party of China and the State Council on Optimizing the Reproductive Policy to Promote the Long term Balanced Development of the Population, the decision for the first time mentioned: standardize the application of human assisted reproductive technology, and lay out a reasonable human assisted reproductive technology service system, which has greatly enhanced our confidence in the assisted reproductive industry." Lin Xiaozhen of Weituo Biology once said.
On August 20 this year, Nuwa Life, a new generation of assisted reproductive technology innovation company, announced that it had won tens of millions of angel investments, which were exclusively invested by JUE Capital.
Nuwa Life has a screening technology for the new generation of test tube baby embryos before transplantation. The technology was invented by four inventors, including Qiao Jie, academician of Peking University, Yu Yang, professor, Fan Yong, vice president of the Third Academy of Guangzhou Medical Sciences, and Liu Jiang, researcher of Beijing Institute of Genomics, Chinese Academy of Sciences. They found that the birth rate of high-quality embryo test tube babies screened by PIMS technology exceeded 70% through clinical experimental cooperation with the team of academician Chen Zijiang of Shandong University. In short, PIMS technology can screen well developed embryos, reduce birth defects of test tube infants, improve the health level of infants, and achieve eugenics.
The Jue Capital team once shared the logic behind this investment: Nuwa Life's new generation IVF screening technology PIMS has a moat built by a deep global exclusive patent, which can directly screen high-quality embryos, reduce the screening cost of IVF and improve the healthy birth rate and fertility quality, with a very strong clinical demand. At the same time, "Nuwa Life" conforms to the national policy of encouraging fertility, and has high social value.
Xu Yi, the head of CICC Qichen Fund under CICC Capital, also said that the liberalization of fertility policy, the increase of infertility rate and the increase of assisted reproduction penetration rate had driven the rapid expansion of China's assisted reproduction industry, and the domestic market for auxiliary reproductive reagents and consumables was monopolized by importers,Domestic substitutionStrong demand, large space.
Here comes the three child policy
After 75-85, it became the main force of childbearing
Behind the popularity is the three child policy.
In May this year, the Political Bureau of the CPC Central Committee held a meeting to review the Decision on Optimizing the Reproductive Policy to Promote Long term Balanced Population Development. The meeting pointed out that in order to improve China's population structure, we will further optimize the birth policy, implement the policy that a couple can have three children and support measures.
The policy of opening up is only the first step of the Long March, and how to improve the childbearing willingness of the young generation and related supporting facilities is the key.
In mid August, the revised draft of the Population and Family Planning Law was submitted to the 30th Session of the Standing Committee of the 13th National People's Congress for deliberation. This is another major revision of the law since the implementation of the comprehensive two child policy and the revision of the Population and Family Planning Law. The revised draft focuses on the implementation of the three child birth policy, the cancellation of social maintenance fees and other restrictive measures, the supporting implementation of positive birth support measures, and strengthening the protection of the rights and interests of family planning families before the implementation of the comprehensive two child policy.
These advantages can, to a certain extent, promote the increase of childbearing demand of some people. Not long ago, Ren Zeping, an online celebrity economist, issued a report that the current main force of fertility is not the post-90s and post-00s, but the post-75-85, that is, their ageBetween 36-46。
Assisted reproductive technology is a new choice for elderly calving and infertility couples. At present, among various technologies of assisted reproduction, the most mainstream way of in vitro fertilization is IVF.
The data shows that the average gross profit rate of China's assisted reproductive services industry is about 70%, which is close to or more than that of medical service branches such as medical beauty and stomatology. The downstream server is the main force of the revenue of the whole assisted reproduction industry chain, and the proportion of the server (industry chain) can reach 60%. This is like a blue ocean to be developed. However, due to the high threshold for downstream access, the middle reaches of the industrial chain may become a breakthrough.
We are concerned about how much it costs to have a child through assisted reproduction. A netizen calculated that the drug cost and inspection cost for each cycle of ovulation promotion was about 2000 yuan, the cost for each cycle of artificial insemination was about 5000 yuan, and the price of IVF ranged from 20000 yuan to 80000 yuan. Among them, the first generation is the cheapest and the third generation is the most expensive. If the first cycle is not successful, the cost will increase accordingly.
Taking Jinxin Reproduction as an example, the number of IVF treatment cycles throughout the year is 22879, and the income of assisted reproduction is about 1.354 billion (excluding the income from auxiliary medical services). The average cost for each case is about59000 yuan。
How big is this market? According to the official website data of the National Health Commission, the infertility rate of women over 35 years old in China is not optimistic. One in every six couples in China has difficulty giving birth. Frost Sullivan's report shows that there are about 47.7 million infertile couples in China. Some experts even predict that infertility will become the third disease threatening human health after cardiovascular and cerebrovascular diseases and tumors.
Couples from all over the country queue up to Chengdu to create people
Supporting 32 billion market value
A number of listed companies have been born at the Assisted Reproduction Track.
Here is a company that has to be mentioned - Jinxin Reproduction, located in Chengdu, the hometown of medicine and beauty. After the launch of the new medical reform in 2009, Chengdu has always been the most developed and active area for medical policies. In terms of the number of medical reform and innovation documents, Chengdu is close to Shenzhen.
According to the data, Fan Yulan, the director of Chengdu Jinjiang Maternal and Child Health Hospital, was the earliest controller of Jinxin Reproduction. In 2010, Fan Yulan led Chengdu Jinjiang Maternity and Child Health Hospital to complete the share reform, turning the original Maternity and Child Health Hospital into today's Chengdu Xinan Maternity Hospital, a private company. After that, she met a good partner Wang Guangxi, the boss of Shanxi coal industry. In 2016, with the help of Sichuan Pension Fund, Wang Guangxi won 49% of the equity of Chengdu Xinan Women's Hospital, and the two started the expansion of Jinxin.
Until 2018, Wang Guangxi was forced to sell the assets of Jinxin due to the rupture of the group's capital chain. In the process of restructuring and M&A of Jinxin Group, capital played an important role. The company attracted many VC/PE and industrial funds, including Warburg Pincus, Xinyin Investment, Sequoia China, Huiqiao Capital, WuXi AppTec, Hillhouse, etc. In June 2019, Jinxin Reproduction was listed on the Hong Kong Stock Exchange, with a market value of HK $24 billion. At present, the company's latest market value exceeds 32 billion Hong Kong dollars.
In space, China's assisted reproductive services resources are unevenly distributed. For a large population province like Sichuan, the capacity of assisted reproductive services has a greater impact on the sustainable development of the population. It is reported that 500 people are born every day in Chengdu alone.
Beikang Medical is a domestic assisted reproduction industrygene sequencing It is the first listed company in the field, and the person at the helm behind it is Liang Bo, a science and engineering student.
Around 2010, at the time of domestic entrepreneurship, he decided to create an innovation driven gene technology company to help tens of millions of infertile couples in China have a healthy baby. In order to learn technology, Liang Bo also went to Shanghai Jiaotong University to study for a doctor of biology.
In 2015, Beikang Medical started to promote the registration of the world's first third-generation IVF products with the State Food and Drug Administration, and was the first to enter the national green channel for innovative medical devices in the field of assisted reproduction in China. In February this year, the company that helped infertility families create people successfully landed on the Hong Kong Stock Exchange.
In addition, the Internet medical platform Micromedicine also focuses on the field of assisted reproduction, and has successively strategically invested in the new IVF Medical Group, acquiring 89.5% of the shares of Genea, an Australian comprehensive assisted reproductive technology service provider. At the same time, with the only Internet maternity and child hospital license in China at present, it integrates the micro medical infertility platform, and also strategically controls Beibei Shell. With the help of the latter's layout of offline reproductive medical union, it accelerates the link between online and offline medical union units and more medical union units.
At present, in addition to the listed companies of Jinxin Reproduction and Beikang Medical, there are many assisted reproduction concept stocks, such as Berry Gene, Changjiang Health, Guangshengtang, Lizhu Pharmaceutical, Meditech, Tongce Medical, Tai'antang, etc.
This year, under the influence of celebrity surrogacy, the share price of Jinxin Reproduction rose for three days. It should be noted that surrogacy is not equivalent to assisted reproduction, which is only a technical means that must be used for pregnancy. Unlike other medical vertical subdivisions, medicine focuses on human health and life span, while assisted reproduction focuses on human reproduction and reproduction, helping families who are unable to have children for various reasons realize their dreams.
Each IVF family has its own joys and sorrows behind it. "There are three ways to be unfilial and having no offspring is the greatest" has always been a deep-rooted traditional concept of the Chinese people. Even if people are more open-minded and their childbearing age is delayed, having children is still the choice of most couples. If assisted reproduction can help them, it can also be regarded as a model for medicine to benefit mankind. Now, people begin to take off their eyeglasses, and assisted reproduction has come into the mainstream.
Figure | Unsplash